Investigational drug · Phase 3
SYHX2008
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diagnosed With Acromegaly, Currently in the Active Stage of the Disease, Gastrointestinal Neuroendocrine Pancreatic Tumor, Acromegaly.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
4
Any phase or sponsor naming "SYHX2008"
First trial start
2024
Apr 16, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SYHX2008", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diagnosed With Acromegaly, Currently in the Active Stage of the Disease
- Gastrointestinal Neuroendocrine Pancreatic Tumor
- Acromegaly
Approved drugs for the same conditions: Pancreatic cancer · Acromegaly · Oncology · Gastroenterology and liver · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "SYHX2008" as an intervention, largest first.
- A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With AcromegalyPivotal-lookingNot yet recruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT07623824 · 154 participants (planned) · Start May 31, 2026 · Primary completion Jul 31, 2029
Drug: SYHX2008; Sandostatin LAR® · For: Diagnosed With Acromegaly, Currently in the Active Stage of the Disease
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT06505395 · 90 participants (planned) · Start Jul 30, 2024 · Primary completion Aug 1, 2027
Drug: SYHX2008 injection; Sandostatin LAR@ · For: Gastrointestinal Neuroendocrine Pancreatic Tumor
Sites: Beijing, China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT07814651 · 78 participants · Start Apr 16, 2024 · Primary completion Apr 9, 2026
Drug: SYHX2008; Sandostatin LAR · For: Acromegaly
Sites: Shanghai, China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT05761431 · 56 participants · Start Mar 2, 2023 · Primary completion Jun 28, 2023
Drug: SYHX2008 injection; Octreotide Acetate Microspheres for Injection injection and 2 more · For: Acromegaly
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.